watson: search

Watson's Naproxen Sodium ER tabs infringes Elan's patent: US District Court

Watson Pharmaceuticals, Inc, a leading specialty pharmaceutical company, announced that the United States District Court for the Southern District of Florida ruled that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan, infringes Elan's US Patent No. 5,637,320 (320 Patent). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc, was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product.

Watson banks on IPL experience for Test success

Shane Watson, the Australian allrounder, hopes his experience of Indian conditions during the IPL will help his case for Test selection next month. Watson, who was the Player of the Series in the IPL, felt he could chip in with short but high-impact spells of bowling as well as propping up the batting.

Watson hopes IPL experience will help in Tests

Shane Watson, the Australian allrounder, hopes his experience of Indian conditions during the IPL will help his case for selection to the XI for the Tests starting next month. Watson, who was the Man of the Series in the IPL, felt he could chip in with short spells of bowling, breaking partnerships and propping up the batting.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., August 13, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Watson Notified of OXYTROL(R) Patent Challenge

2008 OCT 19 - (NewsRx.com) -- Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading specialty pharmaceutical company, confirmed the receipt of a Paragraph IV Certification Notice Letter relating to an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by a generic filer requesting approval to market and sell a generic version of OYXTROL(R) (Oxybutynin Transdermal System). In its Notice Letter, the filer alleges that patents covering OXYTROL are invalid, unenforceable and/or will not be infringed by their manufacture, use or sale of the product described in its ANDA (see also Watson Pharmaceuticals, Inc.).

Genome-based Personalized Medicine

James Watson and Craig Venter might both be Caucasian men, but according to their genes, Watson would metabolize drugs differently than Venter, writes a group led by Venter in Clinical Pharmacology and Therapeutics. The group analyzed six drug-metabolizing genes, including the CYP genes, and found that Venter is an extensive metabolizer and Watson is an intermediate metabolizer with an allele that is rare in Caucasians. "Race-based medicine doesn't have any real basis in science," says Venter in the New Scientist.

Watson Pharma confirms receipt of Paragraph IV Certification Notice Letter relating to ANDA for OXYTROL Patent Challenge - Quick Facts

Watson Pharma. says Phase 3 studies show RAPAFLO effectively reduces symptoms of prostate enlargement - Quick Facts

Watson Notified of OXYTROL(R) Patent Challenge

PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed the receipt of a Paragraph IV Certification Notice Letter relating to an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by a generic filer requesting approval to market and sell a generic version of OYXTROL(R) (Oxybutynin Transdermal System). In its Notice Letter, the filer alleges that patents covering OXYTROL are invalid, unenforceable and/or will not be infringed by their manufacture, use or sale of the product described in its ANDA.

Watson Announces District Court Ruling in Naproxen Sodium Patent

PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. WPI, a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of

Watson rulled out of opening tour match

All-rounder Shane Watson will miss Australia's only serious warm-up ahead of their Test series against India after being ruled out of the four-day game against the Board President's XI with a virus.

Watson to miss warm-up

All-rounder Shane Watson will miss Australia's only serious warm-up ahead of their Test series against India after being ruled out of the four-day game against the Board President's XI with a virus.

Watson offers flexibility that Oz team needs against India: Ponting

Australian all-rounder Shane Watson should find himself penciled in for the first Test against India at Bangalore's Chinnaswamy Stadium next month, because he offers flexibility, both as a batsman and as a fast bowler, says skipper Ricky Ponting.

Watson offers flexibility that Oz team needs against India: Ponting

Australian all-rounder Shane Watson should find himself penciled in for the first Test against India at Bangalore's Chinnaswamy Stadium next month, because he offers flexibility, both as a batsman and as a fast bowler, says skipper Ricky Ponting.

Watson gets Ponting's nod for Test XI return

Ricky Ponting: "He [Shane Watson] could get himself picked in the side as a batter alone, but what he can give us with the ball is a bonus"

Watson rebuilds body, outlook and career

A year ago, when Shane Watson was holed up in his Brisbane apartment thinking his body might never let him be the cricketer he wanted to be, it seemed as improbable as Shane Warne ordering a spicy local delicacy instead of a double-cheese sandwich.

Watson Notified of OXYTROL(R) Patent Challenge

CORONA, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - News), a leading specialty pharmaceutical company, today confirmed the receipt of a Paragraph IV Certification Notice Letter relating to an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by a generic filer requesting approval to market and sell a generic version of OYXTROL® (Oxybutynin Transdermal System). In its Notice Letter, the filer alleges that patents covering OXYTROL are invalid, unenforceable and/or will not be infringed by their manufacture, use or sale of the product described in its ANDA.

Watson ready to replace Symonds

RICKY Ponting has strongly backed Shane Watson to make his return to the Test arena on the tour of India beginning next month.

Watson set to return for second ODI

Injury-plagued Australian all-rounder Shane Watson is set to return in the second one-day clash against Bangladesh at the TIO Stadium on Wednesday.

Watson best replacement for Symonds, says Ponting

Melbourne: Australia skipper Ricky Ponting feels Shane Watson is the best possible replacement for sacked all-rounder Andrew Symonds and has backed him to be in the playing XI during next month’s Test series against India.

Watson: Winning In India Is The Biggest Challenge

Winning in India is the biggest challenge for any Australian cricketer and the four-Test series next month will inspire the young team to rise up to it, all-rounder Shane Watson said on Thursday.

Watson says winning in India the biggest challenge

JAIPUR, India (Reuters) - Winning in India is the biggest challenge for any Australian cricketer and the four-test series next month will inspire the young team to rise up to it, all-rounder Shane Watson said Thursday.

Ponting backs Watson's Test return

Australia skipper Ricky Ponting feels Shane Watson is the best possible replacement for sacked all-rounder Andrew Symonds.

Ponting backs Watson for whirlwind tour (ABC)

Captain Ricky Ponting predicts Queensland all-rounder Shane Watson will be a key player in Australia's upcoming four-Test series against India.

Ponting backs Watson for Test series against India

Australian captain Ricky Ponting has strongly backed all-rounder Shane Watson for the four-match Test series against India starting next month.

Search took 0.03 seconds.